Clinical Trial: Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Study Status: No longer available
Recruit Status: No longer available
Study Type: Expanded Access

Official Title: Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Brief Summary: To provide emergency access to OBI-1 for patients with Acquired Hemophilia and a serious bleeding episode who do not have access to an active clinical study site associated with the OBI-1-301 study.

Detailed Summary:
Sponsor: Baxalta US Inc.

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Baxalta US Inc.

Dates:
Date Received: October 21, 2013
Date Started:
Date Completion:
Last Updated: June 26, 2015
Last Verified: October 2013